Previously doing business as Tessera Diagnostics, Onconome is a biotechnology company dedicated towards developing new, cutting-edge diagnostic products for the early detection of prostate and colon cancer through the discovery, development and commercialization of innovative biomarkers for the early and accurate detection of prostate, colon and other forms of cancer, including lung, breast, liver, pancreatic and stomach. Early detection is the key to successful treatment. The firm's serum tests for early prostate and colon cancer detection have demonstrated remarkable specificity and sensitivity in large studies at Johns Hopkins University. Onconome will also utilize its novel, proteomic technologies to assist pharmaceutical companies in their efforts to develop cancer therapies and will collaborate with in-vivo imaging and targeted therapeutics companies to improve treatment. nsensitive. Onconome tests are non-specific and insensitive. Prostate Specific Antigen (PSA) is a prominent example. The PSA test results in 80% false positive readings and 20% false negative readings, meaning that a vast majority of men with elevated PSA levels actually do not have prostate cancer and, conversely, 20% of men with presumably "normal" PSA levels actually do have prostate cancer. Nevertheless, decisions regarding additional diagnostic tests are made today based upon PSA results, resulting in often unneeded and uncomfortable biopsies. Teh firm's innovative and proprietary tests effectively address the huge unmet need for early cancer detection. Our technology provides Onconome with a distinct and unparalleled competitive advantage in large, unserved, global markets. Work with a collaborator in the highly successful application of a novel proteomics approach to the development of three early cancer detection markers has led Onconome to begin the development of additional markers for several other cancer types.
